SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...
PDUFA Target Action Date for Aficamten Set for September 26, 2025;Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to ...
Cytokinetics, Incorporated announced the granting of stock options and restricted stock units (RSUs) to nine new employees on December 31, 2024, as part of their employment inducement. The company ...
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback